MX2022013182A - Tratamiento de cánceres con un anticuerpo que se une a lgr5 y egfr. - Google Patents
Tratamiento de cánceres con un anticuerpo que se une a lgr5 y egfr.Info
- Publication number
- MX2022013182A MX2022013182A MX2022013182A MX2022013182A MX2022013182A MX 2022013182 A MX2022013182 A MX 2022013182A MX 2022013182 A MX2022013182 A MX 2022013182A MX 2022013182 A MX2022013182 A MX 2022013182A MX 2022013182 A MX2022013182 A MX 2022013182A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- egfr
- antibody
- cancers
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 108060006698 EGF receptor Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 abstract 1
- 101001063456 Homo sapiens Leucine-rich repeat-containing G-protein coupled receptor 5 Proteins 0.000 abstract 1
- 102100031036 Leucine-rich repeat-containing G-protein coupled receptor 5 Human genes 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- 210000003236 esophagogastric junction Anatomy 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/286—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
La presente invención se refiere a medios y métodos en el tratamiento del cáncer. La descripción en particular se refiere a un método para tratar un cáncer en un individuo con un anticuerpo que se une a LGR5 y EGFR. La invención se refiere además a la combinación para su uso en tales métodos y a la combinación para su uso en la manufactura de un medicamento para el tratamiento de cáncer gastrointestinal. Tales anticuerpos son particularmente útiles en el tratamiento de cáncer de unión gástrica, esofágica o gastro-esofágica.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL2025425 | 2020-04-24 | ||
PCT/NL2021/050267 WO2021215926A1 (en) | 2020-04-24 | 2021-04-23 | Treatment of cancers with an antibody that binds lgr5 and egfr |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022013182A true MX2022013182A (es) | 2023-01-16 |
Family
ID=70918928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022013182A MX2022013182A (es) | 2020-04-24 | 2021-04-23 | Tratamiento de cánceres con un anticuerpo que se une a lgr5 y egfr. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230192866A1 (es) |
EP (1) | EP4139357A1 (es) |
JP (1) | JP2023523006A (es) |
KR (1) | KR20230005281A (es) |
CN (2) | CN116731189A (es) |
AU (1) | AU2021261681A1 (es) |
BR (1) | BR112022021345A2 (es) |
CA (1) | CA3176186A1 (es) |
IL (1) | IL297443A (es) |
MX (1) | MX2022013182A (es) |
TW (1) | TW202206460A (es) |
WO (1) | WO2021215926A1 (es) |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10118970B2 (en) | 2006-08-30 | 2018-11-06 | Genentech, Inc. | Multispecific antibodies |
EP2556747B1 (en) | 2008-06-27 | 2020-12-02 | Merus N.V. | Antibody producing transgenic mice |
ES2572728T3 (es) | 2009-03-20 | 2016-06-02 | F. Hoffmann-La Roche Ag | Anticuerpos anti-HER biespecíficos |
NZ630551A (en) | 2012-04-20 | 2017-11-24 | Merus Nv | Methods and means for the production of ig-like molecules |
SG11201507743XA (en) * | 2013-04-22 | 2015-11-27 | Glycotope Gmbh | Anti-cancer treatments with anti-egfr antibodies having a low fucosylation |
US10844127B2 (en) | 2014-02-28 | 2020-11-24 | Merus N.V. | Antibodies that bind EGFR and ErbB3 |
LT3115376T (lt) | 2015-07-10 | 2018-11-12 | Merus N.V. | Antikūnai, kurie jungiasi su žmogaus cd3 |
TWI717401B (zh) | 2015-10-20 | 2021-02-01 | 南韓商東友精細化工有限公司 | 整合有偏光板之窗口基板、及製備該窗口基板之方法 |
MX2018004988A (es) | 2015-10-23 | 2018-11-09 | Merus Nv | Moleculas de union que inhibe el crecimiento de cancer. |
CN113683698B (zh) * | 2017-06-22 | 2023-03-31 | 北海康成(北京)医药科技有限公司 | 预测食管癌对抗erbb3抗体治疗的应答的方法和试剂盒 |
-
2021
- 2021-04-23 JP JP2022564447A patent/JP2023523006A/ja active Pending
- 2021-04-23 MX MX2022013182A patent/MX2022013182A/es unknown
- 2021-04-23 US US17/921,042 patent/US20230192866A1/en active Pending
- 2021-04-23 CN CN202310333976.XA patent/CN116731189A/zh active Pending
- 2021-04-23 CA CA3176186A patent/CA3176186A1/en active Pending
- 2021-04-23 EP EP21722580.4A patent/EP4139357A1/en active Pending
- 2021-04-23 CN CN202180037623.4A patent/CN115698067A/zh active Pending
- 2021-04-23 IL IL297443A patent/IL297443A/en unknown
- 2021-04-23 BR BR112022021345A patent/BR112022021345A2/pt unknown
- 2021-04-23 TW TW110114781A patent/TW202206460A/zh unknown
- 2021-04-23 KR KR1020227041109A patent/KR20230005281A/ko active Search and Examination
- 2021-04-23 AU AU2021261681A patent/AU2021261681A1/en active Pending
- 2021-04-23 WO PCT/NL2021/050267 patent/WO2021215926A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20230005281A (ko) | 2023-01-09 |
AU2021261681A1 (en) | 2022-12-08 |
EP4139357A1 (en) | 2023-03-01 |
TW202206460A (zh) | 2022-02-16 |
IL297443A (en) | 2022-12-01 |
CN116731189A (zh) | 2023-09-12 |
CN115698067A (zh) | 2023-02-03 |
WO2021215926A1 (en) | 2021-10-28 |
BR112022021345A2 (pt) | 2022-12-27 |
CA3176186A1 (en) | 2021-10-28 |
US20230192866A1 (en) | 2023-06-22 |
JP2023523006A (ja) | 2023-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020008882A (es) | Dosificación para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1. | |
CY1123165T1 (el) | Ανοσοσυζευγματα αντι-μεσοθηλινης και χρησεις αυτων | |
MX2018012468A (es) | Construcciones de union a antigeno multiespecificas dirigidas a agentes inmunoterapeuticos. | |
BR112019010356A2 (pt) | molécula de carboidrato, conjugado fármaco-anticorpo (adc), composição, método para preparar a composição, método para tratar câncer em um indivíduo, método para induzir ou melhorar a reação imune em um indivíduo necessitando do mesmo, composto conjugado de fármaco-anticorpo, uso de um composto conjungado anticorpo-fáramco, método para determinar a eficácia terapêutica de células de câncer ao adcc e método para fazer imagem de um indivíduo | |
MX2022011732A (es) | Conjugados de farmacos y anticuerpos anti-ccr7. | |
PE20161096A1 (es) | INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß) | |
MY150756A (en) | Tumor theraphy with an anti-vegf antibody | |
WO2016059602A3 (en) | Combination therapy with anti-her3 antibodies to treat cancer | |
CY1114050T1 (el) | Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου | |
RU2014138039A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака | |
WO2019234241A8 (en) | ANTI-oxMIF/ANTI-CD3 ANTIBODY FOR CANCER TREATMENT | |
MX2020009037A (es) | Anticuerpos de b7-h4 y métodos para usarlos. | |
ZA201907225B (en) | Treatment of her2 positive cancers | |
MX2021001516A (es) | Uso del anticuerpo tim-3 en la preparacion de medicamentos para el tratamiento de tumores. | |
ZA202206993B (en) | Anti-lilrb1 antibody and uses thereof | |
MX2022000710A (es) | Terapia combinada con anticuerpos contra claudin 18.2 e inhibidores del punto de control inmune para el tratamiento del cancer. | |
EA201891528A1 (ru) | Композиции и способы обнаружения и лечения рака желудка | |
MX2022004194A (es) | Anticuerpos contra el receptor de virus de la polio (pvr) y usos de los mismos. | |
ZA202008095B (en) | Humanized antibodies against psma | |
RU2016112421A (ru) | Протиоопухолевое средство и усилитель противоопухолевого эффекта | |
NZ764878A (en) | Human monoclonal antibodies to ganglioside gd2 | |
CR20220127A (es) | Administración de dosis para tratamiento con anticuerpos antagonistas anti-tigit y anti-pd-l1 | |
MX2022013182A (es) | Tratamiento de cánceres con un anticuerpo que se une a lgr5 y egfr. | |
ZA202213434B (en) | Anti-lilrb1 antibody and uses thereof | |
MX2021009514A (es) | Uso de inmunoconjugados anti-ceacam5 para el tratamiento del cancer de pulmon. |